Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Wenqing Qi

Showing results (21-30 of 36) with videos related to

Pageof 4
Sort By:
Leukemia Research|November 17, 2012
Alisertib (MLN8237) an investigational agent suppresses Aurora A and B activity, inhibits proliferation, promotes endo-reduplication and induces apoptosis in T-NHL cell lines supporting its importance in PTCL treatmentWenqing Qi, Catherine Spier, Xiaobing Liu, et al.
Translational Research : the Journal of Laboratory and Clinical Medicine|May 28, 2026
TSG-6 Exacerbates Myocardial Ischemia-Reperfusion Injury by Activating NLRP3 Inflammasome and Regulating Macrophage PolarizationRun Cao, Ruomei Li, Weicheng Bu, et al.
Biochemical Pharmacology|February 5, 2011
Aurora inhibitor MLN8237 in combination with docetaxel enhances apoptosis and anti-tumor activity in mantle cell lymphomaWenqing Qi, Laurence S Cooke, Xiaobing Liu, et al.
Journal of Inflammation Research|February 11, 2025
Metformin Ameliorates Ulcerative Colitis Through Inhibiting NLRP3 Inflammasome ActivationRun Cao, Jing Jing, Yuting Ma, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 1, 2012
Aurora A inhibitor (MLN8237) plus vincristine plus rituximab is synthetic lethal and a potential curative therapy in aggressive B-cell non-Hodgkin lymphomaDaruka Mahadevan, Amy Stejskal, Laurence S Cooke, et al.
Oncotarget|January 6, 2015
Novel receptor tyrosine kinase targeted combination therapies for imatinib-resistant gastrointestinal stromal tumors (GIST)Daruka Mahadevan, Noah Theiss, Carla Morales, et al.
Plos One|June 4, 2014
Alisertib added to rituximab and vincristine is synthetic lethal and potentially curative in mice with aggressive DLBCL co-overexpressing MYC and BCL2Daruka Mahadevan, Carla Morales, Laurence S Cooke, et al.
Cancer Investigation|November 17, 2011
An analog of withaferin A activates the MAPK and glutathione "stress" pathways and inhibits pancreatic cancer cell proliferationXiaobing Liu, Wenqing Qi, Laurence S Cooke, et al.
Scientific Reports|August 19, 2025
Correction: Shikonin inhibits NLRP3 inflammasome activation and controls inflammatory diseaseJing Huang, Mengmeng Dai, Xinyu Huang, et al.
Scientific Reports|May 30, 2025
Shikonin inhibits NLRP3 inflammasome activation and controls inflammatory diseaseJing Huang, Mengmeng Dai, Xinyu Huang, et al.
Pageof 4

Showing results (21-30 of 36) with videos related to

Sort By:
Pageof 4
Leukemia Research|November 17, 2012
Alisertib (MLN8237) an investigational agent suppresses Aurora A and B activity, inhibits proliferation, promotes endo-reduplication and induces apoptosis in T-NHL cell lines supporting its importance in PTCL treatmentWenqing Qi, Catherine Spier, Xiaobing Liu, et al.
Translational Research : the Journal of Laboratory and Clinical Medicine|May 28, 2026
TSG-6 Exacerbates Myocardial Ischemia-Reperfusion Injury by Activating NLRP3 Inflammasome and Regulating Macrophage PolarizationRun Cao, Ruomei Li, Weicheng Bu, et al.
Biochemical Pharmacology|February 5, 2011
Aurora inhibitor MLN8237 in combination with docetaxel enhances apoptosis and anti-tumor activity in mantle cell lymphomaWenqing Qi, Laurence S Cooke, Xiaobing Liu, et al.
Journal of Inflammation Research|February 11, 2025
Metformin Ameliorates Ulcerative Colitis Through Inhibiting NLRP3 Inflammasome ActivationRun Cao, Jing Jing, Yuting Ma, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 1, 2012
Aurora A inhibitor (MLN8237) plus vincristine plus rituximab is synthetic lethal and a potential curative therapy in aggressive B-cell non-Hodgkin lymphomaDaruka Mahadevan, Amy Stejskal, Laurence S Cooke, et al.
Oncotarget|January 6, 2015
Novel receptor tyrosine kinase targeted combination therapies for imatinib-resistant gastrointestinal stromal tumors (GIST)Daruka Mahadevan, Noah Theiss, Carla Morales, et al.
Plos One|June 4, 2014
Alisertib added to rituximab and vincristine is synthetic lethal and potentially curative in mice with aggressive DLBCL co-overexpressing MYC and BCL2Daruka Mahadevan, Carla Morales, Laurence S Cooke, et al.
Cancer Investigation|November 17, 2011
An analog of withaferin A activates the MAPK and glutathione "stress" pathways and inhibits pancreatic cancer cell proliferationXiaobing Liu, Wenqing Qi, Laurence S Cooke, et al.
Scientific Reports|August 19, 2025
Correction: Shikonin inhibits NLRP3 inflammasome activation and controls inflammatory diseaseJing Huang, Mengmeng Dai, Xinyu Huang, et al.
Scientific Reports|May 30, 2025
Shikonin inhibits NLRP3 inflammasome activation and controls inflammatory diseaseJing Huang, Mengmeng Dai, Xinyu Huang, et al.
Pageof 4